Internal Medicine, Rheumatology · Houston, TX
NPI
1346338001
Since 2006
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
2204 Austin St Ste 200
Houston, TX, 77002
Phone (713) 640-5477
Groups this clinician bills Medicare through
Medicare paid, 2024
$259K
23,849 services
Medicare patients, 2024
98
Average age 71
Drug cost, 2024
$4.6M
1,370 prescriptions
Company payments, 2025
$3,089
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jacqueline Vo was code 99214 (office e&m - established), 180 times for 72 patients. In total Jacqueline Vo billed 23,849 services in 33 codes, and Medicare paid $259K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-05-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 180 | 72 | $84.93 | $15K |
| 96413 Chemotherapy Administration | Office | 92 | 15 | $95.58 | $8,793 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 53 | 40 | $11.38 | $603 |
| 76881 Ultrasound - Nonspecific | Office | 24 | 13 | $40.43 | $970 |
| 99215 Office E&M - Established | Office | 24 | 21 | $114.30 | $2,743 |
| 99204 Office E&M - New | Office | 21 | 21 | $121.88 | $2,559 |
By year: 2022 $210K for 15,776 services; 2023 $254K for 21,573 services; 2024 $259K for 23,849 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jacqueline Vo prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 99 prescriptions and refills. In total Jacqueline Vo wrote 1,370 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 99 | 197 | 44 | $2,210 |
| Prednisone Generic | 92 | 139 | 48 | $557 |
| Humira(Cf) Pen Adalimumab | 81 | 86 | 15 | $824K |
| Humira Pen Adalimumab | 73 | 73 | Under 11 | $639K |
| Rinvoq Upadacitinib | 59 | 59 | Under 11 | $360K |
| Gabapentin Generic | 57 | 87 | 25 | $813 |
| Cimzia (2 Pack) Certolizumab Pegol | 55 | 56 | 12 | $340K |
| Orencia Abatacept/Maltose | 52 | 54 | Under 11 | $241K |
| Hydroxychloroquine Sulfate Generic | 51 | 120 | 34 | $1,686 |
| Prolia Denosumab | 50 | 300 | 30 | $80K |
| Simponi Aria Golimumab | 47 | 80 | Under 11 | $338K |
| Remicade Infliximab | 38 | 50 | Under 11 | $224K |
| Leflunomide Generic | 29 | 75 | 19 | $1,987 |
| Enbrel Mini Etanercept | 27 | 30 | Under 11 | $216K |
| Actemra Tocilizumab | 26 | 33 | Under 11 | $154K |
Brand drugs: 769 claims; generic drugs: - claims; opioid claims: 27.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jacqueline Vo $3,089 ($3,089 in general payments such as food, travel and fees) from 24 companies. The largest payer was Abbvie Inc. with $499.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 22 | $499 |
| UCB, Inc. UCB.BR | 15 | $397 |
| Amgen Inc. AMGN | 14 | $273 |
| Argenx US, Inc. ARGX | 4 | $245 |
| Janssen Biotech, Inc. JNJ | 9 | $222 |
| GlaxoSmithKline, LLC. GSK | 11 | $215 |
| Pfizer Inc. PFE | 9 | $199 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $195 |
| ANI Pharmaceuticals, Inc. ANIP | 4 | $128 |
| Novartis Pharmaceuticals Corporation NVS | 6 | $117 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.